Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Tumor Biology
Published in: Tumor Biology 12/2016

01-12-2016 | Original article

RETRACTED ARTICLE: Upregulation of miR-21 and downregulation of miR-494 may serve as emerging molecular biomarkers for prediagnostic samples of subjects who developed nasopharyngeal carcinoma associates with lymph node metastasis and poor prognosis

Authors: Masoomeh Dadpay, Mojtaba Zarea, Rahman Ghaffarzadegan Rabati, Bijan Rezakhaniha, Babak Barari, Vahid Behnod, Katayoun Ziari

Published in: Tumor Biology | Issue 12/2016

Login to get access

Excerpt

RETRACTED ARTICLE: Tumor Biol. …
Appendix
Available only for authorised users
Metadata
Title
RETRACTED ARTICLE: Upregulation of miR-21 and downregulation of miR-494 may serve as emerging molecular biomarkers for prediagnostic samples of subjects who developed nasopharyngeal carcinoma associates with lymph node metastasis and poor prognosis
Authors
Masoomeh Dadpay
Mojtaba Zarea
Rahman Ghaffarzadegan Rabati
Bijan Rezakhaniha
Babak Barari
Vahid Behnod
Katayoun Ziari
Publication date
01-12-2016
Publisher
Springer Netherlands
Published in
Tumor Biology / Issue 12/2016
Print ISSN: 1010-4283
Electronic ISSN: 1423-0380
DOI
https://doi.org/10.1007/s13277-015-3905-1

Other articles of this Issue 12/2016

Tumor Biology 12/2016 Go to the issue

Original Article

Methylation in promoter regions of PITX2 and RASSF1A genes in association with clinicopathological features in breast cancer patients

Original Article

Overexpression of cannabinoid receptor 1 promotes renal cell carcinoma progression

Review

Involvement of microRNAs in HER2 signaling and trastuzumab treatment

Original Article

Up-regulation of small nucleolar RNA 78 is correlated with aggressive phenotype and poor prognosis of hepatocellular carcinoma

Original Article

Identification of miRNAs as non-invasive biomarkers for early diagnosis of lung cancers

Original Article

A humanized chimeric antibody Hai178 targeted to the β subunit of F1F0 ATP synthase
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits